Across TCGA pan-cancer cohorts, GCNT2P1 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GCNT2P1’s most consistent transcriptional readouts.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where GCNT2P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types GCNT2P1 is over-expressed in tumor, although a few such as COAD and BRCA show the opposite, repressed pattern.

UCEC, COAD, and BRCA are the cancer types where GCNT2P1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GCNT2P1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
UCEC	All	All	+0.329	.008	6	view →
COAD	Female	III,IV	−0.156	<.001	5	view →
BRCA	All	III,IV	−0.175	.003	4	view →
KIRC	Male	II,III,IV	−0.078	.032	2	view →
LIHC	Male	All	+0.062	.007	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: GCNT2P1 RNA expression & survival · all GCNT2P1 data types